Current Pneumococcal Vaccination Recommendations
All adults aged ≥50 years should receive a single dose of pneumococcal conjugate vaccine (PCV), with options including PCV20 or PCV21 alone, or PCV15 followed by PPSV23. 1
Available Pneumococcal Vaccines
Three main vaccine types are currently available:
Conjugate Vaccines (PCVs)
- PCV20 (Prevnar20): Covers 20 serotypes, accounts for approximately 30% of invasive pneumococcal disease (IPD) in adults 2
- PCV21 (CAPVAXIVE): FDA-approved in June 2024 for adults ≥18 years 2
- PCV15 (VAXNEUVANCE): Covers 15 serotypes, includes 2 additional serotypes (22F, 33F) beyond PCV13 2
- PCV13 (Prevnar13): Older 13-valent vaccine, largely replaced by newer formulations
Polysaccharide Vaccine
- PPSV23 (Pneumovax23): Covers 23 serotypes but generates weaker immune responses than conjugate vaccines 3
Adult Vaccination Schedules (2024 ACIP Guidelines)
Adults ≥50 Years (Age-Based Recommendation)
For PCV-naïve adults:
Option A (Preferred for simplicity):
- Single dose of PCV20 or PCV21 alone 1
- No additional doses needed
Option B:
- PCV15 followed by PPSV23 at ≥1 year interval 3
This October 2024 recommendation expanded coverage from the previous age threshold of 65 years down to 50 years, recognizing the substantial disease burden in this younger age group 1.
Adults 19-49 Years with Risk Conditions
Risk conditions include: 3
- Chronic heart disease (including heart failure, cardiomyopathies)
- Chronic lung disease (COPD, emphysema, asthma)
- Chronic liver disease
- Diabetes mellitus
- Alcoholism
- Cigarette smoking
Vaccination schedule (same options as above):
- Option A: Single dose PCV20 or PCV21
- Option B: PCV15 followed by PPSV23 at ≥1 year interval 3
Previously Vaccinated Adults
If received PPSV23 only:
- Give PCV20 or PCV15 after ≥1 year interval from last PPSV23 dose 3
If received PCV13 only:
- Give PCV20 after ≥1 year interval, OR
- Give PPSV23 after ≥1 year interval (then reassess at age 65) 3
If received both PCV13 and PPSV23:
- No additional vaccines needed until age 65, then reassess 3
Special Populations: Hematopoietic Stem Cell Transplant (HSCT)
Starting 3-6 months post-HSCT: 3
- Give 3 doses of PCV20, each 4 weeks apart
- Fourth dose of PCV20 given ≥6 months after third dose OR ≥12 months post-HSCT (whichever is later)
Pediatric Vaccination Recommendations
Children <5 Years
As of June 2023, ACIP recommends either PCV15 or PCV20 for all children aged <5 years 2. Korea incorporated PCV15 in April 2024 and PCV20 in October 2025 into their National Immunization Program 4.
Children 6-18 Years with Immunocompromising Conditions
For PCV-naïve children with high-risk conditions (functional/anatomic asplenia including sickle cell disease, HIV, cochlear implants, CSF leaks, other immunocompromising conditions): 5
- Give PCV13 (or newer PCV15/PCV20 if available) first
- Follow with PPSV23 ≥8 weeks later
- Second PPSV23 dose recommended 5 years after first PPSV23 for those with asplenia, HIV, or other immunocompromising conditions 5
High-risk conditions carry dramatically elevated IPD rates: 5
- Hematologic malignancy: 822-fold increased risk
- HIV/AIDS: 122-fold increased risk
- Sickle cell disease: 27-fold increased risk
Key Clinical Considerations
Immunogenicity Evidence
PCV15 demonstrates significantly higher immune responses (OPA GMTRs and IgG GMCRs) for the six shared serotypes compared to PCV13, with comparable safety profiles 6. Both PCV20 and PCV15 provide broader serotype coverage than PCV13 while maintaining robust immunogenicity 2, 6.
Safety Profile
Common adverse reactions in adults include: 7
- Injection site tenderness (86.8-89.0%)
- Redness (30.2-42.9%)
- Swelling (36.9-37.6%)
- Decreased appetite (22.9%)
- Fatigue and irritability (25-31%)
- Fever is uncommon (5.6-6.1%)
In children with sickle cell disease, severe adverse events occurred in 8% (sickle cell crisis 4%, acute chest syndrome 2%, fever 2%), but no deaths were reported 5.
Cost-Effectiveness
Both PCV20 alone and PCV15+PPSV23 are cost-saving for age-based vaccination at 65 years. For combined risk-and-age-based use, PCV20 alone is cost-saving, while PCV15+PPSV23 costs $412,111 per QALY gained 8.
Critical Pitfalls to Avoid
Timing errors: Always wait ≥1 year between PPSV23 and any PCV, or between PCV13 and newer PCVs 3. Shorter intervals may reduce immune responses.
Forgetting reassessment: Adults who received PCV13 and PPSV23 before age 65 need reassessment at age 65 for potential additional doses 3.
Ignoring risk conditions: Don't wait until age 50 for patients with chronic conditions—they qualify for vaccination starting at age 19 3.
Sequential vaccine confusion: If choosing Option B, PCV15 must come BEFORE PPSV23, never the reverse order for optimal immune priming 3.